Liver cancer trial tests new chemo combo without embolization

NCT ID NCT03727633

Terminated Disease control Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tested a liver-directed chemotherapy using idarubicin mixed with lipiodol (a fatty contrast agent) injected directly into the liver artery. The goal was to see if this could control non-spreading liver cancer in 44 patients with cirrhosis. The study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: idarubicin and lipiodol
What this could lead to: If it works, this could offer a new way to control liver cancer in patients who cannot have surgery or other standard treatments.
What could go wrong: This is an early phase 2 trial with only 44 participants, and it was terminated early. The treatment may not control the disease or could cause side effects like liver damage or low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, HEPATOCELLULAR

Contacts and locations

Locations

CHU d'Angers

Angers, 49933, France
CHU de Dijon

Dijon, 21079, France
CHU de Montpellier

Montpellier, 34295, France
CHU de Nice

Nice, 06202, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.